The accuracy of the diagnosis of suspected XXXX ( @entity1443 ) @entity56 : results of a single-blinded trial.

@entity1 @entity566 @entity117 @entity5018 @entity56 @entity272 @entity1443
BACKGROUND: @entity56 to @entity1443 ( @entity1443 ) is rare and very few clinical data are available in the literature. MATERIALS AND METHODS: Eighty-four @entity1 (28 males and 56 females, 5-70 years old) with a suspicion of @entity1443 @entity56 were referred to our drug @entity566 clinic between May 1996 and May 2000. The reaction had occurred 1-96 months prior to the consultation. Single-blinded placebo-controlled oral challenges were carried out in 82 @entity1 , under strict hospital surveillance. RESULTS: Most of the @entity1 experienced @entity272 82/84 (97.6%), with 10 cases of anaphylactic shock (11.9%). Twenty-six (30.9%) reactions were immediate (occurring within the first hour after drug intake), 53 (63.1%) non-immediate and five could not remember. Oral provocation tests (OPT) demonstrated @entity56 in 11 @entity1 only. The two @entity1 not tested (due to a history of life-threatening reaction) were included in the positive group. Thus, 13 (15.5%) @entity1 had @entity1443 @entity56 and 71 (84.5%) had not. All the 13 positive @entity1 had @entity272 , five with anaphylactic shock. 9/13 had immediate reactions. Using OPT, 10 out of 11 had the same clinical reaction but more delayed. In both groups, whether hypersensitive to @entity1443 or not: atopy was similar (7/13-53.8% and 31/71-43.7%), sex ratio was not different (M/F 0.3 and 0.5), 3/13 (23.1%) and 0/71 (0%) had @entity117 / @entity5018 @entity56 . CONCLUSION: The clinical history of @entity1443 ( @entity1443 ) @entity56 is rarely sufficient to set a firm diagnosis and only OPT can confirm this. Careful OPT reproduces the same symptoms (not more severe in our hands) with the same or slightly more delayed chronology. Atopy and sex are not risk factors.
